Acebright Pharma

Acebright ensures and adherence to HSE practices. Our infrastructure for oncology APIs supports capacity of 35MTs plus annually, having line 1 (20MTs) & line 2 (15MTs) separately. Our General APIs facility has capacity of 200MTs plus annually, with line 1 (110MTs) and Line 2 (90MTs) separately. In compliance with US/EU cGMP standard. Total Oncology APIs capacity 35MTs plus annually, having line-1 (20MTs) and line-2 (15MTs) separately. Line-1 is designed for handling of highly potent APIs and Line-2 is designed for manufacture of Tinibs. Line-1 is installed with Isolator for handling powder processing operations. Line-2 is installed with Air handling system with Dust collector with BIBO filters and Wet pad scrubbers. Dedicated Utilities, Quality Unit and Warehouse. In compliance with WHO/US/EU cGMP standard. Total APIs capacity 200MTs plus annually, having line-1 (110MTs) and Line-2 (90MTs) separately. Dedicated Utilities, Quality Unit and Warehouse. Prequalified by WHO Geneva. Started as Intermed Pharma to manufacture of intermediates to APIs. Unit-2 was commissioned to manufacture advanced intermediates. Commenced manufacturing of Capecitabine (Oncology APIs). Commenced manufacturing of First General APIs (Efavirenz). Company name changed as Cdymax (India) Pharma Pvt. Ltd. New Production Block (PB-2) commissioned to manufacture of Oncology APIs and sarted manufacturing from July 2011. Company name changed as Acebright (India) Pharma Pvt. Ltd., in April 2012. Production Block (PB-1) renovated for manufacturing of General APIs. WHO Geneva Approval.